The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.
Dosimetry is essential for Peptide Receptor Radionuclide Therapy (PRRT) of meningiomas, to predict efficacy and dose-effect relationships at the individual level, and to move towards personalized medicine. Due to the increasing therapeutic applications of Lutathera, the European Association of Nuclear Medicine (EANM) recently issued recommendations on the dosimetry of 177Lu-labeled somatostatin analogues. Nevertheless, despite these recommendations, the evaluation of meningioma tumor dosimetry in Peptide Receptor Radionuclide Therapy studies is not systematic, which has not enabled us to clearly determine the dose delivered to the meningioma lesion in these treatments and the possible dose-response relationship in this type of treatment.
Study Type
OBSERVATIONAL
Enrollment
11
The tumoral dosimetry has been done on patient after treatment by 177Lu-DOTATATE Theses patients performed a scintigraphy exam at D1, D4 and D7 after the treatment
CHRU de NANCY
Vandœuvre-lès-Nancy, France
Nuclear medicine Department CHRU de NANCY
Vandœuvre-lès-Nancy, France
Diagnostic accuracy for progression free survival
Accuracy of tumor dosimetry to predict 6-month progression-free survival.
Time frame: Day 1
Diagnostic accuracy for overal survival
Accuracy of tumoral dosimetry in predicting 6-month overall survival
Time frame: Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.